Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 202-206

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

By Dornhorst Anne   Lüddeke Hans-Joachim   Honka Marek   Ackermann Ralf W.   Meriläinen Markus   Gallwitz Baptist   Sreenan Seamus    

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 369-376

Informa Healthcare

Access to resources Recommend Favorite

An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK

By Palmer Andrew J.   Valentine William J.   Ray Joshua A.   Foos Volker   Lurati Francesco   Smith Inger   Lammert Morten   Roze Stéphane  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 895-901

Informa Healthcare

Access to resources Recommend Favorite

Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study

By Hermansen Kjeld   Dornhorst Anne   Sreenan Seamus  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2601-2608

Informa Healthcare

Access to resources Recommend Favorite

Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy

By Davis Keith L.   Tangirala Muralikrishna   Meyers Juliana L.   Wei Wenhui  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1083-1091

Informa Healthcare

Access to resources Recommend Favorite